Efficacy of low-dose gemcitabine chemotherapy on pancreatic cancer patients with mutant of solute carrier family 29, member 1 gene T1288A

Abstract

Objective To observe the efficacy and adverse effects of low-dose gemcitabine chemotherapy in pancreatic cancer patients with mutant of solute carrier family 29, member 1 (SLC29A1) gene T1288A. Methods A total of 72 pancreatic cancer patients with mutant of SLC29A1 gene T1288A were included in this study. They were randomly assigned to the experimental group (low-dose gemcitabine, 600 mg/m2) and the control group (standard-dose gemcitabine, 1 000 mg/m2), both groups included 36 patients. The curative effect and adverse reactions were observed and evaluated. Results There was no significant difference of the efficacy between the experimental group and the control group. The incidences of leukopenia, thrombocytopenia, erythrocyte reduction, vomiting, liver damage, diarrhea, rash and itching, the incidence of influenza-like symptoms were 3 (8.3%), 3 (8.3%), 4 (11.1%), 6 (16.7%), 2 (5.6%), 3 (8.3%), 1 (2.8%), 1 (2.8%) in the group of low-dose gemcitabine chemotherapy and 12 (33.3%), 15 (41.7%), 13 (36.1%), 20 (55.6%), 2 (5.6%), 4 (11.1%), 1 (2.8%), 1 (2.8%) in the group of standard-dose gemcitabine chemotherapy. The adverse effects indexes which leukopenia (P=0.009), thrombocytopenia (P=0.001), erythrocyte reduction (P=0.013), and vomiting (P=0.001) were statistically significant between two groups. There was no statistically significant difference between the two groups in June and 1 year survival by survival analysis. Conclusion For pancreatic cancer patients with mutant of SLC29A1 gene T1288A, there is a similar effect and less incidence of adverse effects in the experimental group when compared to the control group. Key words: Gemcitabine; Pancreatic cancer; Solute carrier family 29, member 1 gene; Human equilibrative nucleoside transporter 1